Skip to main content
ARQT
NASDAQ Life Sciences

Arcutis Swings to Profit in Q2 as ZORYVE Revenue Surges 59%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$29.86
Mkt Cap
$3.39B
52W Low
$13.695
52W High
$31.77
52W Position info
118% above low
Off High info
6.0% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ARQT has more than doubled off its 52-week low of $13.695.

Summary

Arcutis Biotherapeutics reported Q2 2026 net income of $15.0 million on product revenue of $129.9 million, a 59% increase year-over-year, driven by strong ZORYVE sales. The company also disclosed new 10b5-1 trading plans for its CEO and CLO.


Key Events · Earnings and Guidance · ARQT

  • Q2 Revenue Surges 59%

    Driven by ZORYVE foam and cream formulations, product revenue reached $129.9 million, up from $81.5 million in Q2 2025.

  • Swings to Profitability

    Marking a significant inflection, net income was $15.0 million, compared to a net loss of $15.9 million in the prior-year quarter.

  • Strong Cash Position

    As of June 30, 2026, cash, equivalents, restricted cash, and marketable securities totaled $238.9 million, providing at least 12 months of runway.

  • Insider Trading Plans Adopted

    CEO Todd Watanabe adopted a 10b5-1 plan for up to 325,000 options, and CLO Masaru Matsuda adopted a plan for up to 40,000 options and 45,792 shares, both effective in late August/September 2026.


Analysis · ARQT · Life Sciences

For the first time in recent history, Arcutis delivered a profitable quarter, fueled by robust ZORYVE demand across all formulations. Product revenue jumped 59% year-over-year to $129.9 million, flipping a $15.9 million net loss into a $15.0 million net profit. The quarter ended with $238.9 million in cash and investments, providing ample runway. However, the CEO and CLO adopted new 10b5-1 trading plans in June, signaling potential future insider sales that could weigh on sentiment.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARQT was trading at $29.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $13.70 to $31.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARQT - Latest Insights

ARQT
Nov 05, 2026, 11:52 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $26.96
Real-time Price: $27.15 info
Change: +$0.190 (+0.70%) info
Market Cap: $3.436B info
ARQT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.00
Real-time Price: $27.15 info
Change: -$1.85 (-6%) info
Market Cap: $3.436B info
ARQT
Nov 04, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $27.15 info
Change: -$4.10 (-13%) info
Market Cap: $3.436B info
ARQT
Nov 04, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.30
Real-time Price: $27.15 info
Change: -$5.15 (-16%) info
Market Cap: $3.436B info
ARQT
Nov 04, 2026, 4:00 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $34.23
Real-time Price: $27.15 info
Change: -$7.08 (-21%) info
Market Cap: $3.436B info